全文获取类型
收费全文 | 14008篇 |
免费 | 911篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 216篇 |
儿科学 | 390篇 |
妇产科学 | 318篇 |
基础医学 | 1994篇 |
口腔科学 | 359篇 |
临床医学 | 1287篇 |
内科学 | 2896篇 |
皮肤病学 | 474篇 |
神经病学 | 1387篇 |
特种医学 | 369篇 |
外科学 | 1184篇 |
综合类 | 108篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 1531篇 |
眼科学 | 319篇 |
药学 | 977篇 |
中国医学 | 50篇 |
肿瘤学 | 1118篇 |
出版年
2023年 | 150篇 |
2022年 | 276篇 |
2021年 | 528篇 |
2020年 | 274篇 |
2019年 | 461篇 |
2018年 | 556篇 |
2017年 | 340篇 |
2016年 | 332篇 |
2015年 | 404篇 |
2014年 | 568篇 |
2013年 | 722篇 |
2012年 | 1068篇 |
2011年 | 1036篇 |
2010年 | 618篇 |
2009年 | 496篇 |
2008年 | 801篇 |
2007年 | 806篇 |
2006年 | 731篇 |
2005年 | 769篇 |
2004年 | 663篇 |
2003年 | 611篇 |
2002年 | 543篇 |
2001年 | 148篇 |
2000年 | 112篇 |
1999年 | 184篇 |
1998年 | 110篇 |
1997年 | 87篇 |
1996年 | 80篇 |
1995年 | 80篇 |
1994年 | 67篇 |
1993年 | 63篇 |
1992年 | 107篇 |
1991年 | 97篇 |
1990年 | 92篇 |
1989年 | 78篇 |
1988年 | 67篇 |
1987年 | 74篇 |
1986年 | 58篇 |
1985年 | 54篇 |
1984年 | 62篇 |
1983年 | 61篇 |
1982年 | 38篇 |
1981年 | 32篇 |
1980年 | 32篇 |
1979年 | 59篇 |
1978年 | 45篇 |
1977年 | 30篇 |
1976年 | 27篇 |
1974年 | 41篇 |
1970年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
6.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
7.
Dolores Herreros Mariano García-Arranz Isabel Pascual Damián García-Olmo 《Experimental dermatology》2006,15(6):482-482
Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
8.
9.
D J Enscore J L Osborne J E Shaw 《Methods and findings in experimental and clinical pharmacology》1989,11(3):173-178
The in vitro and in vivo functionality of Catapres-TTS, a transdermal therapeutic system that delivers the alpha adrenergic receptor agonist clonidine, is discussed in terms of the drug transport kinetics and resultant plasma drug concentration profiles. The design of Catapres-TTS is presented as an optimization by which the best combination of system performance characteristics is obtained within the inherent limitations of the transdermal drug transport properties and the known pharmacokinetic and pharmacodynamic properties of the drug. Clonidine is a potent antihypertensive agent with a relatively low therapeutic index. For Catapres-TTS, the majority of control over the drug input rate resides within the system, rather than within the skin, which significantly reduces the variability in drug input rate and resulting plasma drug concentration both within and between patients. Moreover, the presence of a rate-control element in the system allows for patterning of the drug release rate. An initial bolus of drug is placed in the contact adhesive layer, where its transport into the skin is not inhibited by the rate control element in the system, for reduction in the time needed to achieve steady state drug input. The selection of the loading dose of drug is described as an optimization between the minimization of the lag time and the maintenance of constant plasma drug concentrations during the crossover period between system applications in chronic therapy. 相似文献
10.
Aneurisma de aorta abdominal infrarrenal en asociación con riñón en herradura: aportación de un caso
Nerea Senarriaga Ruiz de la Illa Reyes Vega Manrique Isabel Lacasa Viscasillas Iñaki Iriarte Soldevilla Miguel Unda Urzaiz 《Actas urologicas espa?olas》2009,33(10):1141-1144
We review the association between surgically resolvable aortic disease and horseshoe kidney with a discussion of diagnostic problems and therapeutic options.Male patient 81 years of age with horseshoe kidney and an abdominal aortic aneurysm that was discovered by chance in an abdominal ultrasound during a check-up for his prostate condition.A retroperitoneal approach was used in order to resect the aneurysm and perform an aorto-aortic bypass with no complications occurring. Two years after the diagnosis, the patient is still asymptomatic from a vascular point of view.The co-presence of horseshoe kidney and aortic disease needing surgical correction is infrequent, but it significantly increases the technical complexity of aortic reconstruction. A literature review is included. 相似文献